{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:21:17Z","timestamp":1779888077607,"version":"3.53.1"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,1,25]]},"abstract":"<jats:p>A 65-year-old woman had been visiting our department for the treatment of type-2 diabetes mellitus since December 2012. Her glycated haemoglobin levels were well controlled (\u22485.8% (40\u2005mmol\/mol)) by metformin (500\u2005mg). In July 2014, her white cell count increased suddenly to 33\u2005530 cells\/\u03bcL and she was diagnosed with Ph+ chronic myeloid leukaemia. She was started on dasatinib (100\u2005mg), which immediately normalised plasma levels of WCC. Dasatinib improved the glycaemic index to &lt;6.0% and also improved plasma levels of triglycerides (TGs) and high-density lipoprotein-cholesterol (HDL-c). Levels of low-density lipoprotein-cholesterol were increased but remained within the normal range. The TG:HDL-c ratio and Quantitative Insulin Sensitivity Check Index rapidly improved. Followed by an improvement in insulin sensitivity, plasma levels of adiponectin and leptin were increased. This case study suggests that dasatinib might have positive as well as negative effects on the metabolism of glucose and lipids.<\/jats:p>","DOI":"10.1136\/bcr-2015-214284","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T05:33:28Z","timestamp":1455255208000},"page":"bcr2015214284","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia"],"prefix":"10.1136","volume":"2016","author":[{"given":"Katsumi","family":"Iizuka","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0086"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/OTT.S35360","article-title":"Systematic review of dasatinib in chronic myeloid leukemia","volume":"6","author":"Breccia","year":"2013","journal-title":"Onco Targets Ther"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.02.016"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.7.2402"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.5","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.6","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6910com"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810246105"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501758102"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.9","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0080"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.10","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0003"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.11","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801896103"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075"},{"key":"2025082623275792000_2016.feb12_1.bcr2015214284.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052500"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-214284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:28:10Z","timestamp":1756276090000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-214284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":13,"alternative-id":["10.1136\/bcr-2015-214284"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-214284","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}